…
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -151.75M | -130.24M | -66.58M | -85.01M | -54.96M |
| Net income | -154.94M | -131.19M | -66.82M | -85.51M | -55.15M |
| Selling general administrative | 59.84M | 52.20M | 40.90M | 35.78M | 34.11M |
| Selling and marketing expenses | 2.54M | - | - | - | - |
| Gross profit | -83.46M | 29.60M | -37.16M | -27.39M | -18.51M |
| Reconciled depreciation | 2.23M | 1.28M | 1.49M | 1.44M | 1.14M |
| Ebit | -156.55M | -160.04M | -89.98M | -75.88M | -58.66M |
| Ebitda | -154.01M | -184.78M | -113.15M | -65.00M | -60.27M |
| Depreciation and amortization | 2.54M | -24.74M | -23.18M | 10.88M | -1.61M |
| Operating income | -156.55M | -160.04M | -89.98M | -75.88M | -58.66M |
| Other operating expenses | 200.49M | 201.62M | 139.08M | 105.82M | 89.79M |
| Interest expense | 14.51M | 2.72M | 0.13M | 18.56M | 6.45M |
| Tax provision | 2.54M | 0.96M | 0.24M | 0.50M | 0.19M |
| Interest income | - | 2.72M | - | 0.30M | 1.89M |
| Net interest income | 10.75M | 2.72M | -0.13M | 0.30M | 1.89M |
| Income tax expense | 3.19M | 0.96M | 0.24M | 0.50M | 0.19M |
| Total revenue | 43.95M | 41.59M | 49.11M | 29.94M | 31.13M |
| Total operating expenses | 197.95M | 201.62M | 139.08M | 105.82M | 89.79M |
| Cost of revenue | 127.41M | 11.98M | 86.27M | 57.33M | 49.64M |
| Total other income expense net | 4.80M | 29.80M | 23.40M | -9.13M | 3.70M |
| Net income from continuing ops | -176.76M | -131.19M | -66.82M | -85.51M | -55.15M |
| Net income applicable to common shares | - | -131.19M | -66.82M | -85.51M | -55.15M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 458.49M | 376.54M | 456.60M | 231.22M | 263.38M |
| Intangible assets | 1.80M | 1.95M | 2.35M | 2.84M | 2.88M |
| Other current assets | 9.66M | 2.20M | 2.17M | 1.06M | 4.95M |
| Total liab | 102.15M | 129.49M | 140.40M | 128.95M | 132.08M |
| Total stockholder equity | 356.34M | 247.06M | 316.20M | 102.26M | 131.30M |
| Other current liab | 40.13M | 37.99M | 22.51M | 22.01M | 13.54M |
| Common stock | 5.88M | 4.75M | 4.48M | 3.21M | 2.92M |
| Capital stock | 5.88M | 4.75M | 4.48M | 3.21M | 2.92M |
| Retained earnings | -753.06M | -598.12M | -466.93M | -400.11M | -314.60M |
| Other liab | - | 38.77M | 66.24M | 79.69M | 91.42M |
| Other assets | - | 6.85M | 2.50M | 2.36M | 2.19M |
| Cash | 205.05M | 147.75M | 241.44M | 163.08M | 197.61M |
| Total current liabilities | 69.09M | 78.93M | 71.90M | 46.75M | 36.79M |
| Current deferred revenue | 22.68M | 29.42M | 34.66M | 20.18M | 18.84M |
| Net debt | -192.88M | -134.28M | -237.68M | -159.13M | -192.36M |
| Short term debt | 1.67M | 1.68M | 1.49M | 1.43M | 1.38M |
| Short long term debt total | 12.16M | 13.47M | 3.75M | 3.95M | 5.25M |
| Other stockholder equity | 1126.05M | 870.87M | 787.87M | 490.09M | 441.39M |
| Property plant equipment | - | 24.84M | 7.28M | 8.02M | 8.93M |
| Total current assets | 368.81M | 306.44M | 424.18M | 217.99M | 247.37M |
| Long term investments | 57.31M | 36.46M | 20.30M | 0.00M | 2.01M |
| Net tangible assets | - | 245.10M | 313.85M | 99.42M | 128.42M |
| Short term investments | 150.13M | 142.48M | 168.99M | 44.67M | 42.15M |
| Net receivables | 3.98M | 4.70M | 6.67M | 1.75M | 2.65M |
| Inventory | 0.00M | 9.31M | 4.91M | 7.43M | - |
| Accounts payable | 4.60M | 9.83M | 13.24M | 3.13M | 3.03M |
| Accumulated other comprehensive income | -22.53M | -30.45M | -9.22M | 9.07M | 1.59M |
| Common stock total equity | - | - | - | 3.21M | 2.92M |
| Non currrent assets other | 2.87M | 4.81M | 2.08M | 1.95M | 1.91M |
| Non current assets total | 89.68M | 70.10M | 32.42M | 13.22M | 16.01M |
| Capital lease obligations | 12.16M | 13.47M | 3.75M | 3.95M | 5.25M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -24.05M | 2.80M | -146.62M | -1.49M | 26.77M |
| Change to liabilities | - | -29.92M | 19.85M | -19.36M | -17.99M |
| Total cashflows from investing activities | - | 2.80M | -146.62M | -1.49M | 24.17M |
| Total cash from financing activities | 230.09M | 58.74M | 281.95M | 39.52M | 74.23M |
| Change to operating activities | - | 9.12M | 1.01M | 4.13M | 2.18M |
| Net income | -154.94M | -131.19M | -66.82M | -85.51M | -55.15M |
| Change in cash | 56.60M | -93.31M | 78.47M | -34.53M | 33.08M |
| Begin period cash flow | 148.45M | 241.75M | 163.28M | 197.81M | 164.73M |
| End period cash flow | 205.05M | 148.44M | 241.75M | 163.28M | 197.81M |
| Total cash from operating activities | -142.21M | -149.90M | -59.63M | -79.90M | -63.05M |
| Issuance of capital stock | 225.71M | 57.74M | 265.11M | 38.07M | 74.18M |
| Depreciation | 2.54M | 1.28M | 1.49M | 1.44M | 1.14M |
| Other cashflows from investing activities | - | - | - | - | 26.77M |
| Change to inventory | - | - | 1.03M | 4.13M | 2.29M |
| Change to account receivables | 1.73M | 1.83M | -4.99M | 1.15M | 0.63M |
| Sale purchase of stock | - | - | -0.28M | - | 74.23M |
| Other cashflows from financing activities | -0.45M | 1.00M | 17.13M | 1.45M | 0.05M |
| Change to netincome | - | -1.02M | -10.17M | 18.25M | 6.15M |
| Capital expenditures | 3.98M | 7.64M | 0.87M | 1.29M | 2.60M |
| Change in working capital | -25.75M | -18.97M | 15.87M | -14.08M | -15.18M |
| Stock based compensation | 26.23M | 24.54M | 17.09M | 9.37M | 7.83M |
| Other non cash items | 8.88M | -23.93M | -27.25M | 9.00M | -1.60M |
| Free cash flow | -146.19M | -157.54M | -60.50M | -81.19M | -65.65M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
| Name | Title | Year Born |
|---|---|---|
| Dr. Sven Ante Lundberg M.D. | CEO, Pres, Principal Financial Officer & Exec. Director | 1963 |
| Mr. Peter B. Silverman J.D. | Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal | 1978 |
| Mr. Hui Liu Ph.D. | Chief Bus. Officer, Exec. VP & Head of Merus U.S. | 1967 |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor | NA |
| Harry Shuman | Chief Accounting Officer | NA |
| Mr. Cornelis Adriaan de Kruif Ph.D. | CTO & Exec. VP | 1965 |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Sr. VP | NA |
| Ms. Jillian Connell | VP of Investor Relations & Corp. Communications | NA |
| Mr. Alexander Berthold Hendrik Bakker Ph.D. | Chief Devel. Officer & Exec. VP | 1967 |
| Dr. Andrew Joe M.D. | Chief Medical Officer & Sr. VP | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.